Drugmakers need to learn empathy and not try to defend price hikes that make drugs inaccessible, Andrew Witty, the chief executive of British pharmaceutical giant GSK, told CNBC.
“In all circumstance, we need to be realistic and empathetic, we need to demonstrate better that we understand people are concerned about [drug pricing],” Witty told CNBC on the sidelines of the Singapore Summit 2016.
“I’m not, for a second, going to sit here and defend any historical pricing position,” he added.
Drug prices have come under scrutiny in recent months after Mylan received public backlash for the sharp price increases the Epipen, an injection device to treat fatal anaphylactic shocks from food allergies or insect bites. The price of a two-pack Epipen has risen to nearly $600, from just $100 in 2007.
Pharmaceutical companies have also been a favorite target of both Democrat candidate Hillary Clinton and GOP nominee Donald Trump during the 2016 presidential elections campaign.
Trump has even commented about the potential savings that the U.S. Medicare program could reap if it negotiates directly with drug-makers, something currently prohibited by law. Last September, Clinton tweeted about the “price gorging” of Daraprim, a treatment often used by HIV/AIDS patients, drawing attention to Martin Shkreli, the former CEO of Turing Pharmaceuticals which owns the drug.
“There is a real issue here on affordability… it almost doesn’t matter whether or not you can defend the price because if people can’t afford it, that’s what we have to focus on,” Witty said.
“[Drug] pricing always has to be taken in a very responsible mindset to get the balance right between access and reward for innovation,” he added.
By Pauline Chiou and Aza Wee Sile
Source: CNBC
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
